U.S. Drug

Methylenedioxymethamphetamine (MDMA), known by the street names ecstasy, XTC, X, Adam, clarity, and lover s speed, was synthesized in 1914 as an appetite suppressant but was never marketed. In the early 1970s, it appeared on the U.S. drug scene under various street names. More recently, the name ecstasy has become synonymous fot MDMA, even in the scien-... 

Work supported in part by Public Health Service grant DA 01642 and by funding from the World Health Organization, the U.S. Drug Enforcement Administration, the VCU Grant-in-Aid Program, and the A.D. Williams Fund. 

F-D-C Reports Pharmaceutical Approvals Monthly. Pharmaceutical Approvals Monthly [99] provides coverage of U.S. drug approvals at the clinical level and includes the most recent FDA list of NDA approvals (originals, supplementals, and ANDAs). This specialized monthly also focuses on new drugs that have either been recently approved or... 

Source U.S. Drug Enforcement Agency (2001). Information available at http //www. 

A synopsis of the history of U.S. drug legislation is presented in Table 2.1. Here we will review the history of the three major legislative acts covering pharmaceuticals. 

Website of the U.S. Drug Enforcement Administration. Contains legal information about drug use and abuse. 

Physicians establish the U.S. Pharmacopoeia, the first U.S. drug standards. 

To illustrate this point, Grabowski and Vernon examined the new product sales for the U.S. drug companies that spent between 300 and 500 million on their global R D in the mid-1980s (the top tier group in that period). They found that subsequent new product sales emanating from these R D efforts varied between 100 million and 3 billion (after 7 years of marker life). ... 

Therefore, to be marketed as a pharmaceutical, a botanical must traverse the modern regulatory process resulting in an approved NDA. The fact that no botanical is currently NDA-approved has caused many to speculate whether a botanical could ever make it through the rigorous U.S. drug development process, and still others to ask why one would choose to pursue this avenue, given the panoply of regulatory options already available to botanicals in the United States. 

Santerre, Rexford E., John A. Vernon, and Carmelo Giacotto. The Impact of Indirect Government Controls on U.S. Drug Prices and R D. Cato... 

The international drug law and regulation situation presents still another influence on the ability of U.S. drug firms to generate sales and hence R D dollars. Although many... 

---